Geneva, Rotterdam, Sydney – 6 February 2018
The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and DNDi to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
Geneva, Rotterdam, Sydney – 6 February 2018
Paris, Geneva – 31 January 2018
Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being developed in collaboration with the Drugs for Neglected Disease initiative (DNDi). It would be the first all-oral treatment under investigation for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), commonly known as sleeping sickness. This treatment is expected to contribute to the elimination of the disease.
[Kuala Lumpur/Geneva – 13 November 2017]
Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd (Pharmaniaga), Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration agreement to manufacture and supply a new hepatitis C treatment regimen to be sold for US$300 in the public sector in Malaysia.
[Cape Town – 8 November 2017]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) and the Global Antibiotic Research & Development Partnership (GARDP) today opened a new liaison office in Cape Town, South Africa.
[Geneva – 4 November 2017]
Results open possibility of paradigm shift in treatment of deadly disease
The first all-oral treatment for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT) has been proven to be effective and safe, according to the results of clinical trials led by the Drugs for Neglected Diseases initiative (DNDi) and its partners, published today in the Lancet.
[Español] [Français] [Português]
[Kuala Lumpur, Geneva – 20 September 2017]
Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to expensive treatments for this viral disease.
[Bahasa] [Español] [Português]
[Berlin – 4 September 2017]
Germany hosts pledging event for GARDP, a new initiative to develop new antibiotic treatments
Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.
[Geneva – 8 August 2017]
The Drugs for Neglected Diseases initiative (DNDi) announced today the appointment of Dr Marie-Paule Kieny as the new Chair of the Board of Directors. Dr Kieny, a former World Health Organization (WHO) Assistant Director-General, brings more than four decades of experience in public health and innovation to DNDi’s work in developing new treatments for neglected patients. Until July 2017, Dr Kieny led WHO’s Health Systems and Innovation cluster. During her career at WHO, she also led its Innovation, Information, Evidence and Research cluster, directed the WHO Initiative for Vaccine Research and led the organization’s activities on Ebola and Zika research, as well as the preparation of an R&D Blueprint to accelerate global preparedness for future pandemics. Before joining WHO in 2001, Dr Kieny was Director of Research at the Institute of Virology, Institut national de la Santé et de la Recherche médicale in Paris (INSERM) and Assistant Scientific Director of French biopharmaceutical company Transgene SA.
[Geneva – 7 July 2017]
Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection—much harder, and sometimes impossible, to treat.
[Boston, Geneva – 6 July 2017]
First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea.
[Deutsch] [Français] [Português]
[Khartoum, Sudan – 19 June 2017]
First ever double-blind study for disease so neglected that it only recently was added to WHO list of neglected tropical diseases
The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre (MRC) in Khartoum, Sudan.
[London and New York – May 3, 2017]
Indian, UK and US students to help discover desperately-needed drug leads for visceral leishmaniasis
The non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) has launched a collaborative project with five universities in India, the UK, and the US to harness the capacity of university teaching laboratories and task students with discovering potential new drugs for patients living with neglected diseases.
[Geneva, Switzerland – April 19, 2017]
The pharmaceutical company Merck has become the sixth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early-stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
[Los Angeles, USA – April 13, 2017]
A study of almost 5,000 Latin American-born residents of Los Angeles County found that 1.24% tested positive for Chagas disease, a parasitic infection that can cause life-threatening heart damage if not treated early. Chagas disease is one of the leading causes of heart failure in Latin America.
[Tokyo, Japan – March 30, 2017]
Daiichi Sankyo announces collaborative research on drugs for neglected diseases
Daiichi Sankyo Company, Limited (hereafter, “Daiichi Sankyo”), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (hereafter, “DNDi”) with regard to a new research program, the Hit-to-Lead Project, with the aim to develop drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
[Seattle, USA – February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.
[Geneva, Switzerland – October 22, 2016]
Potentially refutes assumption that Loa Loa is a benign disease and highlights R&D gap for filarial diseases
A filarial worm infection called Loiasis that affects over 10 million people in Africa and has been assumed to be a relatively harmless disease could possibly contribute to increased risk of death, according to a study recently published in Lancet Infectious Diseases.
[Geneva, Switzerland – September 22, 2016]
The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research & Development Partnership (GARDP) launched earlier this year.
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing ‘4-in-1’ fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).